Article
Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myeloid leukemia.
American journal of hematology - 1 May 2023
Lo Min-Yen, Tsai Xavier Cheng-Hong, Lin Chien-Chin, Tien Feng-Ming, Kuo Yuan-Yeh, Lee Wan-Hsuan, Peng Yen-Ling, Liu Ming-Chih, Tseng Mei-Hsuan, Hsu Cheng-An, Chen Jui-Che, Lin Liang-In, Sun Hsun-I, Chuang Yi-Kuang, Ko Bor-Sheng, Tang Jih-Luh, Yao Ming, Chou Wen-Chien, Hou Hsin-An, Tien Hwei-Fang
Abstract excerpt
The European LeukemiaNet (ELN) recently proposed a revised recommendation for the diagnosis and management of acute myeloid leukemia (AML) in adults, recognized as ELN-2022. However, validation in a large real-world cohort remains lacking. In this study, we aimed to validate the prognostic relevance of the ELN-2022 in a cohort of 809 de novo, non-M3, younger (ages 18-65 years) AML patients receiving standard...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.